Skip to main content
SpringerLink
Log in

Breast Cancer

  • Chapter
  • First Online:
Cancer and Sexual Health

Part of the book series: Current Clinical Urology ((CCU))

Abstract

In the United States, breast cancer is the most common cancer diagnosed in women and is second to lung cancer as the leading cause of cancer death [1]. It is estimated that there will be 194,280 cases of breast cancer diagnosed and 40,610 deaths from breast cancer in 2009 [1]. Of the new diagnoses, 192,370 will be in women and 1,910 will be in men [1]. Breast cancer in men is significantly more likely to be estrogen-receptor positive [2] and is associated with risk factors including testicular and benign breast conditions, age, family history, Klinefelter syndrome, and Jewish ancestry.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, et al. SEER Cancer Statistics Review, 1975–2006. Bethesda, MD: National Cancer Institute; 2009.

    Google Scholar 

  2. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med. 2002;137:678–87.

    PubMed  Google Scholar 

  3. Surveillance, Epidemiology, and End Results (SEER) Program: Limited-use data (1973–2006), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009, based on the November 2007 submission (www.seer.cancer.gov).

  4. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544–73.

    PubMed  Google Scholar 

  5. Kurian AW, Chun NM, Mills MA, et al. A clinic-based study of BRCA 1/2 mutation epidemiology in Asians. Breast Cancer Res Treat. 2006;100:S273–74.

    Google Scholar 

  6. Lindau ST, Schumm LP, Laumann EO, Levinson W, O’Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med. 2007;357(8):762–74.

    PubMed  CAS  Google Scholar 

  7. Dow KH, Ferrell BR, Leigh S, Ly J, Gulasekaram P. An evaluation of the quality of life among long-term survivors of breast cancer. Breast Cancer Res Treat. 1996;39(3):261–73.

    PubMed  CAS  Google Scholar 

  8. Walsh SR, Manuel JC, Avis NE. The impact of breast cancer on younger women’s relationships with their partner and children. Families, Systems, & Health. 2005;23(1):80–93.

    Google Scholar 

  9. Lindau ST, Surawska H, Paice J, Baron SR. Communication about sexuality and intimacy in couples affected by lung cancer and their clinical-care providers. Psycho-Oncology 2010;20(2):179–185

    Google Scholar 

  10. Schmidt NK, Woods TE, Steward JA. Domestic violence against women with cancer: examples and review of the literature. J Support Oncol. 2006;4:24–8.

    PubMed  Google Scholar 

  11. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890–907.

    PubMed  CAS  Google Scholar 

  12. Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis. 2009;199(9):1263–9.

    PubMed  Google Scholar 

  13. Burchell AN, Winer RL, de Sanjosé S, Franco EL. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006;24 Suppl 3:S52–61.

    Google Scholar 

  14. Goldin R, Lloyd J. HIV and hepatobiliary disease. Curr Diagn Pathol. 2002;8:144–51.

    Google Scholar 

  15. Smith KP, Christakis NA. Social networks and health. Ann Rev Sociol. 2008;34:405–29.

    Google Scholar 

  16. U.S. Department of Health and Human Services. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2006.

    Google Scholar 

  17. Gray J, Evans N, Taylor B, Rizzo J, Walker M. State of the Evidence The Connection Between Breast Cancer and the Environment. International Journal of Occupational and Environmental Health 2009;15(1):43–78.

    Google Scholar 

  18. Pichini S, Zuccaro P, Pacifici R. Drugs in semen. Clin Pharmacokinet. 1994;26(5):356–73.

    PubMed  CAS  Google Scholar 

  19. Lindau ST, Laumann EO, Levinson W, Waite LJ. Synthesis of scientific disciplines in pursuit of health: the Interactive Biopsychosocial Model. Perspect Biol Med. 2003;46(3):S74–86.

    PubMed  Google Scholar 

  20. Sandefur RL, Laumann EO. A paradigm for social capital. Rationality Society. 1998;10(4):481–501.

    Google Scholar 

  21. Staton AD, Kurian AW, Cobb K, Mills MA, Ford JM. Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. Familial Cancer. 2008;7(2):179–86.

    PubMed  Google Scholar 

  22. Basson R, Berman J, Burnett A, et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Sex Marital Ther. 2001;27(2):83–94.

    Google Scholar 

  23. Tabâar L, Duffy SW, Vitak B, Chen HH, Prevost TC. The natural history of breast carcinoma: what have we learned from screening? Cancer. 1999;86(3):449–62.

    Google Scholar 

  24. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2009;59(1):27–41.

    PubMed  Google Scholar 

  25. U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151(10):716–26.

    Google Scholar 

  26. Calonge N, Petitti DB, DeWitt TG, Dietrich AJ, Gregory KD, Grossman D, et al. Screening for Breast Cancer: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine 2009;152(3):199–200.

    Google Scholar 

  27. Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009;151:738–47.

    PubMed  Google Scholar 

  28. Smith RA, Saslow D, Sawyer KA, et al. American Cancer Society guidelines for breast cancer ­screening: update 2003. CA Cancer J Clin. 2003;53(3):141–69.

    PubMed  Google Scholar 

  29. Smith RA, Saslow D, Andrews Sawyer K, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin. 2003;53(3):141–69.

    PubMed  Google Scholar 

  30. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57(2):75–89.

    PubMed  Google Scholar 

  31. Murff HJ, Greevy RA, Syngal S. The comprehensiveness of family cancer history assessments in primary care. Community Genet. 2007;10(3):174–80.

    PubMed  Google Scholar 

  32. Eisen A, Weber BL. Prophylactic mastectomy for women with BRCA1 and BRCA2 mutations – facts and controversy. N Engl J Med. 2001;345(3):207–8.

    PubMed  CAS  Google Scholar 

  33. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346(21):1616–22.

    PubMed  Google Scholar 

  34. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93:1633–7.

    PubMed  CAS  Google Scholar 

  35. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91(17):1475–9.

    PubMed  CAS  Google Scholar 

  36. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2008;122(9):2017–22.

    PubMed  CAS  Google Scholar 

  37. Lindau ST, Leitsch SA, Lundberg KL, Jerome J. Older women’s attitudes, behavior, and communication about sex and HIV: a community-based study. J Womens Health. 2006;15(6):747–53.

    Google Scholar 

  38. Matloff ET, Barnett RE, Bober SL. Unraveling the next chapter sexual development, body image, and sexual functioning in female BRCA carriers. Cancer J. 2009;15(1):15–8.

    PubMed  Google Scholar 

  39. Brandberg Y, Sandelin K, Erikson S, et al. Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol. 2008;26(24):3943–9.

    PubMed  Google Scholar 

  40. Holland R, Veling SH, Mravunac M, Hendriks JH. Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer. 1985;56(5):979–90.

    PubMed  CAS  Google Scholar 

  41. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41.

    PubMed  Google Scholar 

  42. Ganz PA. Sexual functioning after breast cancer: a conceptual framework for future studies. Ann Oncol. 1997;8(2):105–7.

    PubMed  CAS  Google Scholar 

  43. Rowland JH, Meyerowitz BE, Crespi CM, et al. Addressing intimacy and partner communication after breast cancer: a randomized controlled group intervention. Breast Cancer Res Treat. 2009;118(1):99–111.

    PubMed  Google Scholar 

  44. Trinkaus M, Chin S, Wolfman W, Simmons C, Clemons M. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist. 2008;13(3):222–31.

    PubMed  Google Scholar 

  45. Speer JJ, Hillenberg B, Sugrue DP, et al. Study of sexual functioning determinants in breast cancer survivors. Breast J. 2005;11(6):440–7.

    PubMed  Google Scholar 

  46. Fisher C. The invisible dimension: abuse in palliative care families. J Palliat Med. 2003;6(2):257–64.

    PubMed  Google Scholar 

  47. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227–32.

    PubMed  Google Scholar 

  48. Alderman AK, Hawley ST, Janz NK, et al. Racial and ethnic disparities in the use of postmastectomy breast reconstruction: results from a population-based study. J Clin Oncol. 2009;27(32):5325–30.

    PubMed  Google Scholar 

  49. Christian CK, Niland J, Edge SB, et al. A multi-institutional analysis of the socioeconomic determinants of breast reconstruction – a study of the National Comprehensive Cancer Network. Ann Surg. 2006;243(2):241–9.

    PubMed  Google Scholar 

  50. Morrow M, Mujahid M, Lantz PM, et al. Correlates of breast reconstruction – results from a population-based study. Cancer. 2005;104(11):2340–6.

    PubMed  Google Scholar 

  51. Markopoulos C, Tsaroucha AK, Kouskos E, Mantas D, Antonopoulou Z, Karvelis S. Impact of breast cancer surgery on the self-esteem and sexual life of female patients. J Int Med Res. 2009;37(1):182–8.

    PubMed  CAS  Google Scholar 

  52. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8):2672–85.

    PubMed  CAS  Google Scholar 

  53. Dizon DS. Quality of life after breast cancer: survivorship and sexuality. Breast J. 2009;15(5):500–4.

    PubMed  Google Scholar 

  54. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and a 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.

    Google Scholar 

  55. Trudeau M, Charbonneau F, Gelmon K, et al. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol. 2005;6(11):886–98.

    PubMed  CAS  Google Scholar 

  56. Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006;24(7):1045–51.

    PubMed  Google Scholar 

  57. Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22(20):4174–83.

    PubMed  Google Scholar 

  58. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21(6):976–83.

    PubMed  CAS  Google Scholar 

  59. Sparano J, Wang M, Martino S, et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every three weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. J Clin Oncol. 2007;25:516.

    Google Scholar 

  60. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431–9.

    PubMed  CAS  Google Scholar 

  61. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable Her-2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84.

    PubMed  CAS  Google Scholar 

  62. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):971–7.

    PubMed  CAS  Google Scholar 

  63. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106.

    PubMed  CAS  Google Scholar 

  64. Taylor CW, Green S, Dalton WS, et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with ­receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol. 1998;16(3):994–9.

    PubMed  CAS  Google Scholar 

  65. Brinton LA, Sherman ME, Carreon JD, Anderson WF. Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst. 2008;100(22):1643–8.

    PubMed  Google Scholar 

  66. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001;93(9):684–90.

    PubMed  CAS  Google Scholar 

  67. Harvey HA, Lipton A, Max DT, Pearlman HG, Diaz-Perches R, de la Garza J. Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer. J Clin Oncol. 1985;3(8):1068–72.

    PubMed  CAS  Google Scholar 

  68. Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol. 2001;19(2):343–53.

    PubMed  CAS  Google Scholar 

  69. Klijn JG. LHRH-agonist versus chemotherapy in premenopausal breast cancer? Eur J Cancer. 2002;38 Suppl 6(6):S45–6.

    Google Scholar 

  70. Epstein MT. Side effects of zoledronic acid. Bone. 2007;40(6):S297.

    Google Scholar 

  71. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679–91.

    PubMed  CAS  Google Scholar 

  72. ATAC Trialists’ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45–53.

    Google Scholar 

  73. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747–57.

    PubMed  Google Scholar 

  74. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25(5):486–92.

    PubMed  CAS  Google Scholar 

  75. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361(8):766–76.

    PubMed  CAS  Google Scholar 

  76. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369(9561):559–70.

    PubMed  CAS  Google Scholar 

  77. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366(9484):455–62.

    PubMed  CAS  Google Scholar 

  78. Jonat W, Gnant M, Boccardo F, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 2006;7(12):991–6.

    PubMed  CAS  Google Scholar 

  79. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262–71.

    PubMed  CAS  Google Scholar 

  80. Ingle J, Dowsett M, Cuzick J, et al. Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies. Breast Cancer Res Treat. 2008;69(suppl):66s (abstract 12).

    Google Scholar 

  81. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666–76.

    PubMed  CAS  Google Scholar 

  82. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for Her-2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–43.

    PubMed  CAS  Google Scholar 

  83. Goldfarb SB, Dickler MN, Fruscione M, Barz T, Atkinson T, Hudis CA, et al. Sexual dysfunction in women with breast cancer: measuring prevalence and severity. J Clin Oncol. 2009;27:15s.

    Google Scholar 

  84. Mourits MJ, Bockermann I, de Vries EG, et al. Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy. Br J Cancer. 2002;86(10):1546–50.

    PubMed  CAS  Google Scholar 

  85. Su HI, Sammel MD, Springer E, Freeman EW, DeMichele A, Mao JJ. Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors. Breast Cancer Res Treat. 2010;124(1):205–11.

    PubMed  CAS  Google Scholar 

  86. Mok K, Juraskova I, Friedlander M. The impact of aromatase inhibitors on sexual functioning: current knowledge and future research directions. Breast. 2008;17:5.

    Google Scholar 

  87. Kwan KW, Chlebowski RT. Sexual dysfunction and aromatase inhibitor use in survivors of breast cancer. Clin Breast Cancer. 2009;9(4):219–24.

    PubMed  CAS  Google Scholar 

  88. Ravdin PM, Cronin KA, Howlander N, Chlebowski RT, Berry DA. A sharp decrease in breast cancer incidence in the United States in 2003. Breast Cancer Res Treat. 2006;100 Suppl 1:S6.

    Google Scholar 

  89. Bordeleau L, Pritchard K, Goodwin P, Loprinzi C. Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. Clin Ther. 2007;29(2):230–41.

    PubMed  CAS  Google Scholar 

  90. van der Laak JAWM, de Bie L, de Leeuw H, de Wilde PCM, Hanselaar AGJM. The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerised cytometry. J Clin Pathol. 2002;55:446–51.

    PubMed  Google Scholar 

  91. Gelfand M, Wendman E. Treating vaginal dryness in breast cancer patients: results of applying a polycarbophil moisturizing gel. J Womens Health. 1994;3(6):427–33.

    Google Scholar 

  92. Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial [comment]. J Natl Cancer Inst. 2000;92(13):1054–64.

    PubMed  CAS  Google Scholar 

  93. van der Laak JAWM, Schijf CP, Kerstens HMJ, Heijnen-Wijnen THM, de Wilde PCM, Hanselaar AGJM. Development and validation of a computerized cytomorphometric method to assess the maturation of vaginal epithelial cells. Cytometry. 1999;35:196–202.

    PubMed  Google Scholar 

  94. Haefner HK. Critique of new gynecologic surgical procedures: surgery for vulvar vestibulitis. Clin Obstet Gynecol. 2000;43(3):689–700.

    PubMed  CAS  Google Scholar 

  95. Labrie F, Cusan L, Gomez JL, et al. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause. 2009;16(1):30–6.

    PubMed  Google Scholar 

  96. Loprinzi CL, Wolf SL, Barton DL, Laack NNI. Symptom management in premenopausal patients with breast cancer. Lancet Oncol. 2008;9(10):993–1001.

    PubMed  Google Scholar 

  97. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87–94.

    PubMed  Google Scholar 

  98. Willhite LA, O’Connell MB. Urogenital atrophy: prevention and treatment. Pharmacotherapy. 2001;21(4):464–80.

    PubMed  CAS  Google Scholar 

  99. Howard FM, Perry P, et al. Pelvic pain: diagnosis & management. Baltimore, MD: Lippincott Williams & Wilkins; 2000.

    Google Scholar 

  100. Barton D, Wilwerding M, Carpenter L, Loprinzi C. Libido as part of sexuality in female cancer survivors. Oncol Nurs Forum. 2004;31(3):11.

    Google Scholar 

  101. Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med. 2006;166(14):1483–9.

    PubMed  CAS  Google Scholar 

  102. IMS Health Incorporated. National Disease and Therapeutic Index, January 2000–December 2009. IMS Health, Plymouth Meeting PA, 2010.

    Google Scholar 

  103. Harris GB, Markowski M. Successful treatment of orgasmic dysfunction using specialized physical therapy. a case report. J Reprod Med. 2009;54(8):520–2.

    PubMed  Google Scholar 

  104. Rosenbaum TY, Owens A. The role of pelvic floor physical therapy in the treatment of pelvic and genital pain-related sexual dysfunction. J Sex Med. 2008;5:513–23.

    PubMed  Google Scholar 

  105. Srivastava R, Thakar R, Sultan A. Female sexual dysfunction in obstetrics and gynecology. Obstet Gynecol Surv. 2008;63(8):527–37.

    PubMed  Google Scholar 

  106. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97(1):30–9.

    PubMed  CAS  Google Scholar 

  107. Ginzburg R, Wong Y, Fader JS. Effect of bupropion on sexual dysfunction. Ann Pharmacother. 2005;39(12):2096–9.

    PubMed  CAS  Google Scholar 

  108. Kotlyar M, Brauer LH, Tracy TS, et al. Inhibition of CYP2D6 activity by bupropion. J Clin Psycho­pharmacol. 2005;25(3):226–9.

    PubMed  CAS  Google Scholar 

  109. Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry. 2000;61(4):276–81.

    PubMed  CAS  Google Scholar 

  110. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63(4):357–66.

    PubMed  Google Scholar 

  111. Heiman JR. Psychologic treatments for female sexual dysfunction: are they effective and do we need them? Arch Sex Behav. 2002;31(5):445–50.

    PubMed  Google Scholar 

  112. American Cancer Society. Cancer facts and figures 2007–2008. Atlanta, GA: American Cancer Society; 2008.

    Google Scholar 

  113. Faddy MJ, Gosden RG. A model conforming the decline in follicle numbers to the age of menopause in women. Hum Reprod. 1996;11(7):1484–6.

    PubMed  CAS  Google Scholar 

  114. Hong S, Nekhlyudov L, Didwania A, Olopade O, Ganschow P. Cancer survivorship care: exploring the role of the general internist. J Gen Intern Med. 2009;24:S495–500.

    PubMed  Google Scholar 

  115. Hewitt M, Sheldon G, Stovall E. From cancer patient to cancer survivor: lost in transition. Washington, DC: National Academies Press; 2006.

    Google Scholar 

  116. Oeffinger KC, McCabe MS. Models for delivering survivorship care. J Clin Oncol. 2006;24(32):5117–24.

    PubMed  Google Scholar 

  117. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19): 1793–802.

    PubMed  CAS  Google Scholar 

  118. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21(21):4042–57.

    PubMed  CAS  Google Scholar 

  119. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25(25):3808–15.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge Ms. Janelle Sobecki, MA, Ms. Emily Abramsohn, MPH, Ms. Katherine Githens, Ms. Andreea Mihai, and Mr. Matt Dias for their research assistance. The authors extend their deep gratitude to Julie Park, MD, breast reconstructive surgeon at the University of Chicago Medical Center, for photographic contributions.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Department of Medicine-Geriatrics, The University of Chicago, 5841 S. Maryland Avenue, MC 2050, Chicago, IL, 60637, USA

    Stacy Tessler Lindau

Authors
  1. Stacy Tessler Lindau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stacey Sandbo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shari Beth Goldfarb
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maura N. Dickler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stacy Tessler Lindau .

Editor information

Editors and Affiliations

  1. Sexual Medicine Program, Memorial Sloan-Kettering Cancer Center, East 68th Street 353, New York, 10021, New York, USA

    John P. Mulhall

  2. Daniel den Hoed Cancer Center, Dept. Radiation Oncology, Erasmus Medical Center, Groene Hilledijk 301, Rotterdam, 3075 EA, Netherlands

    Luca Incrocci

  3. Alvarado Hospital, Alvarado Road 6719, San Diego, 92120, California, USA

    Irwin Goldstein

  4. New England Research Institutes, Galen Street 9, Watertown, 02472, Massachusetts, USA

    Ray Rosen

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Lindau, S.T., Sandbo, S., Goldfarb, S.B., Dickler, M.N. (2011). Breast Cancer. In: Mulhall, J., Incrocci, L., Goldstein, I., Rosen, R. (eds) Cancer and Sexual Health. Current Clinical Urology. Humana Press. https://doi.org/10.1007/978-1-60761-916-1_28

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-916-1_28

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-915-4

  • Online ISBN: 978-1-60761-916-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation